Back to Search
ANTONI RIBAS, MD
MD
Hematology & Oncology Physician
NPI: 1730109331IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A76097(CA)
Education
OTHER
Class of 1990
Research & Publications (20)
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
PMID 19640287·J Transl Med·2009
3-trial
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
PMID 19118070·Clin Cancer Res·2009
8-other
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
PMID 19001146·Oncologist·2008
6-review
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
PMID 17673618·Oncologist·2007
6-review
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
PMID 16133107·Cancer Immunol Immunother·2006
7-preclinical
Clinical trials with tumor antigen genetically modified dendritic cells.
PMID 16338421·Semin Oncol·2005
8-other
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
PMID 16204013·J Clin Oncol·2005
3-trial
Genetically modified dendritic cells for cancer immunotherapy.
PMID 16457651·Curr Gene Ther·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 MEDICAL PLAZA, #365,420,530,120
LOS ANGELES, CA 90095 - Phone
- (310) 206-3928
Quick Facts
- NPI
- 1730109331
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile